Get started
Author

Hisataka Ominato

Stapes Bar—Normal Stapedial Superstructure with a Mobile Footplate Fixed to the Promontory
2023 · Shiori Suzuki, Isamu Kunibe, et al. · Ear Nose & Throat Journal · 2
PDF
Removal of Coin Cell Lithium Battery Lodged in the Pediatric Pharyngoesophageal Junction by Rigid Esophagoscopy; a Case Report.
2022 · Hisataka Ominato, Takumi Kumai, et al. · Archives of Academic Emergency Medicine · 2
PDF
Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan
2026 · Akira Ohkoshi, Katsunori Katagiri, et al. · Oral Oncology · 1
Combined positive score using 28–8 predicts nivolumab efficacy in HNSCC
2026 · Ryosuke Sato, Takahiro Inoue, et al. · Oral Oncology · 1
Cervical Syphilitic Lymphadenitis in Initially Suspected Malignant Disease
2025 · Hisataka Ominato, Ryo Ota, et al. · Annals of Internal Medicine Clinical Cases · 1
Hypopharyngeal Diffuse Large B-Cell Lymphoma in a 74-Year-Old Man Presenting with Dysphagia: A Case Report
2023 · Hisataka Ominato, Yuki Komabayashi, et al. · American Journal of Case Reports · 1
PDF
Man with pharyngeal discomfort and dysphagia
2023 · Hisataka Ominato, Yuki Komabayashi · Journal of the American College of Emergency Physicians Open · 1
PDF
Central-part laryngectomy after laryngotracheal separation to manage pharyngocutaneous fistula: A case report and retrospective analysis of 12 cases
2022 · Kenzo Ohara, Akihiro Katada, et al. · Auris Nasus Larynx · 1
PDF
Up-regulation of CXCR3 on tonsillar T-cells in patients with IgA nephropathy
2026 · Risa Wakisaka, Takumi Kumai, et al. · Clinical & Experimental Immunology
Association of tonsillar Pseudomonas identified by 16S rRNA sequencing with clinical remission after tonsillectomy in IgA nephropathy: a machine learning approach
2026 · Ryosuke Sato, Michihisa Kono, et al. · Clinical and Experimental Nephrology
Real-world surgical outcomes and prognostic factors in stage III–IVA laryngeal squamous cell carcinoma: a multicenter, retrospective, cohort study in northern Japan
2026 · Akira Ohkoshi, Katsunori Katagiri, et al. · International Journal of Clinical Oncology
PDF
Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy
2026 · Ryosuke Sato, Shota Sakaue, et al. · Cancer Immunology Immunotherapy
A Low‐Cost, Easily Implementable Model for Multiskill Hands‐On Training in Otolaryngology Education
2026 · Takahiro Inoue, Shota Sakaue, et al. · Laryngoscope Investigative Otolaryngology
Data from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Works count: 41
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type